A phase III, multicenter, randomized, double-blind, placebo-controlled trial, evaluating maintenance Alpelisib in association with trastuzumab and pertuzumab for metastatic HER2+ BC with PIK3CA mutation, is ongoing [100]. The gene discussed is PIK3CA; the disease is breast cancer.